Another warrant that will be listed but has an acceleration clause..
Medexus Pharmaceuticals closes $32.52M bought deal
2021-02-23 08:43 MT - News Release
Medexus Pharmaceuticals Inc. has closed its previously announced bought deal public offering of 4,581,689 units at a price of $7.10 per unit for total gross proceeds of approximately $32,529,992, including 597,611 units sold pursuant to the exercise in full of the overallotment option granted to the underwriters (as defined herein).
The offering was led by Raymond James Ltd. and Stifel GMP, as co-lead underwriters and joint bookrunners, on behalf of a syndicate of underwriters consisting of Roth Canada, ULC, Bloom Burton Securities Inc. and Mackie Research Capital Corp. Each unit consists of one common share and one-half of one common share purchase warrant. Each warrant entitles the holder thereof to purchase one common share at a price equal to $10 until Feb. 23, 2023. In the event that the volume weighted average trading price of the common shares on the TSX Venture Exchange for 10 consecutive trading days exceeds $14, the company may, within 10 business days of the occurrence of such event, deliver a notice (including a press release) to the holders of warrants accelerating the expiry date of the warrants to the date that is 30 days following the date of such notice. The warrants issued pursuant to the offering have been conditionally approved for listing and are expected to commence trading on the TSX-V under the symbol MDP.WT shortly following the closing of the offering, subject to the satisfaction of all listing conditions.
stockwatch.com |
